Nootropics
Semax
Semax is a peptide-based nootropic studied for cognitive support research. Below, we compare vendors currently stocking research-grade Semax — not just a single sales page.
Semax is a peptide-based nootropic studied for cognitive support research. Below, we compare vendors currently stocking research-grade Semax — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 Amino ClubBest Value |
From $29.95 | Third-party COA | Buy Here → | |
 Amino Vault |
$62.90 | Third-party COA | Buy Here → | |
 American Peptides |
$65.00 | Third-party COA | Buy Here → |
Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-10), developed in Russia and studied since the 1980s as a nootropic and neuroprotective research candidate. It is approved as a prescription medication in Russia for certain neurological indications.
Research-grade Semax is typically supplied as a lyophilized powder or pre-mixed solution in sealed vials, commonly at 5mg to 30mg strengths, intended for laboratory research use only.
Semax lacks the hormonal (corticotropic) activity of full ACTH but is studied for its effects on brain-derived neurotrophic factor (BDNF) expression and central nervous system signaling, mechanisms researchers have linked to its studied cognitive and neuroprotective effects.
Semax has been studied in Russian clinical and preclinical research for effects on attention, memory, and learning, and is approved in Russia for use in certain conditions involving cognitive impairment.
A portion of the literature has examined Semax in animal models of ischemic brain injury, where researchers have investigated its potential neuroprotective and anti-inflammatory effects on brain tissue.
Semax holds regulatory approval in Russia but does not have FDA approval in the United States, and independent Western trial data is limited. Reported concerns in available research and anecdotal use are generally mild, including nasal irritation with intranasal administration; comprehensive long-term human safety data outside Russian clinical use remains limited.
Clinical protocols studied in Russian trials used intranasal administration at doses defined in that regulatory context; no FDA-established human dosage exists in the United States.
Compound X does not sell Semax directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
Semax research is indexed on PubMed under search terms such as "Semax ACTH analog" and "Semax neuroprotective nootropic."
New guides, vendor comparisons and compound breakdowns every week.